Abstracts Archive - Page 409 of 2607 - ACR Meeting Abstracts

Abstract Number: 1693 • ACR Convergence 2023
Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures
Alice Horisberger¹, Alec Griffith¹, Arnon Arazi², Joshua Keegan¹, Kaitlyn Howard¹, Takanori Sasaki¹, Tusharkanti Ghosh³, Andrea Fava⁴, Jun Inamo⁵, John Pulford¹, Ekaterina Murzin¹, Brandon Hancock¹, Katie Preisinger⁶, Maria Gutierrez-Arcelus⁷, Thomas Eisenhaure⁸, Joel Guthridge⁹, Paul Hoover¹⁰, Maria Dall'Era¹¹, David Wofsy¹¹, Diane L. Kamen¹², Kenneth Kalunian¹³, Richard Furie¹⁴, H Michael Belmont¹⁵, Peter Izmirly⁶, Robert Clancy¹⁶, David Hildeman¹⁷, steve Woodle¹⁷, William Apruzzese¹⁸, Maureen McMahon¹⁹, Jennifer Grossman²⁰, Jennifer Barnas²¹, Fernanda Payan-Schober²², Mariko Ishimori²³, Accelerating Medicines Partnership Program RA SLE Network²³, Matthias Kretzler²⁴, Celine Berthier²⁴, Jeff Hodgin²⁴, Dawit Demeke²⁴, Chaim Putterman²⁵, Nir Hacohen⁸, Michael Brenner¹, Jennifer Anolik²¹, Anne Davidson²⁶, Judith James⁹, Soumya Raychaudhuri¹⁰, Michelle Petri²⁷, Jill Buyon¹⁶, Betty Diamond²⁶, The Accelerating Medicines Partnership In RA/SLE²⁸, Fan Zhang²⁹, James Lederer¹ and Deepak Rao¹⁰, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Broad Institute of MIT and Harvard, Melrose, MA, ³School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, ⁴Johns Hopkins University, Baltimore, MD, ⁵University of Colorado School of Medicine, Aurora, CO, ⁶New York University School of Medicine, New York, NY, ⁷Boston Children's Hospital, Boston, MA, ⁸Broad Institute of MIT and Harvard, Cambridge, MA, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹University of California San Francisco, San Francisco, CA, ¹²Medical University of South Carolina, Charleston, SC, ¹³University of California San Diego, La Jolla, CA, ¹⁴Northwell Health, Manhasset, NY, ¹⁵NYU School of Medicine, New York, NY, ¹⁶NYU Grossman School of Medicine, New York, NY, ¹⁷University of Cincinnati College of Medicine, Cincinnati, OH, ¹⁸Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, ¹⁹UCLA David Geffen School of Medicine, Los Angeles, CA, ²⁰University of California Los Angeles, Los Angeles, CA, ²¹University of Rochester Medical Center, Rochester, NY, ²²Texas Tech University Health Sciences Center, El Paso, TX, ²³Cedars-Sinai Medical Center, Los Angeles, CA, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Albert Einstein College of Medicine, Bronx, NY, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁸multisites, multisites, ²⁹University of Colorado, Aurora, CO
Background/Purpose: Patients with lupus nephritis (LN) have variable responses to standard-of-care therapy, and a third of patients with class III, IV, or V show a…
Abstract Number: 1697 • ACR Convergence 2023
Molecular Characterisation of Remission and Lupus Low Disease Activity State (LLDAS) by Whole-Blood Transcriptome-Based Pathways in a Pan-European Systemic Lupus Erythematosus Cohort
Ioannis Parodis¹, Julius Lindblom¹, Guillermo Barturen², Rafaela Ortega Castro³, Ricard Cervera⁴, Jacques-Olivier Pers⁵, Fernanda Genre Romero⁶, Falk Hiepe⁷, Maria Gerosa⁸, Laszlo Kovacs⁹, Ellen De Langhe¹⁰, Silvia Piantoni¹¹, Georg Stummvoll¹², Carlos Vasconcelos¹³, Barbara Vigone¹⁴, Torsten Witte¹⁵, Marta Alarcon-Riquelme¹⁶ and Lorenzo Beretta¹⁷, ¹Karolinska Institutet, Stockholm, Sweden, ²Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ³Hospital Reina Sofía, Cordoba, Spain, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Centre Hospitalier Universitaire de Brest, Hospital de la Cavale Blanche, Brest, France, ⁶IDIVAL, Santander, Spain, ⁷Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁸University of Milan, Milano, Italy, ⁹University of Szeged, Szeged, Hungary, ¹⁰Katholieke Universiteit Leuven and Universitair Ziekenhuis Leuven, Leuven, Belgium, ¹¹ASST Spedali Civili and University of Brescia, Brescia, Italy, ¹²Medical University Vienna, Baden, Austria, ¹³Centro Hospitalar do Porto, Porto, Portugal, ¹⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ¹⁵Dept of Immunology and Rheumatology, Hannover, Germany, ¹⁶Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹⁷Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Italy
Background/Purpose: Treating to remission or lupus low disease activity state (LLDAS) are conceptual frameworks for the management of SLE, but the biological milieus underlying these…
Abstract Number: 1698 • ACR Convergence 2023
High-throughput Proteomics Identities a Spectrum of Novel Serum Biomarkers of Lupus Nephritis
Huihua Ding, Yiwei Shen, Min Dai and Nan Shen, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Navigating the molecular complexity of lupus nephritis (LN), a heterogeneous autoimmune disorder, poses challenges to biomarker discovery. This study addresses these challenges through an…
Abstract Number: 1699 • ACR Convergence 2023
Immunosuppression with Targeted Therapies Reduces Morbidity and Mortality in Pre-Capillary Pulmonary Hypertension Associated with Systemic Sclerosis: A EUSTAR Analysis
Cosimo Bruni¹, Havard Fretheim², Lorenzo Tofani³, Yannick Weber¹, Eric Hachulla⁴, Patricia Carreira⁵, Dilia Giuggioli⁶, Paolo Airò⁷, Elise Siegert⁸, Ulf Müller-Ladner⁹, marco Matucci Cerinic¹⁰, Gabriela Riemekasten¹¹, Carmen Pilar Simeon-Aznar¹², Jeska de Vries-Bouwstra¹³, Lesley Ann Saketkoo¹⁴, Joerg Distler¹⁵, Alexandra Balbir-Gurman¹⁶, Ivan Castellvi¹⁷, Elisabetta Zanatta¹⁸, Vanessa Smith¹⁹, Christopher Denton²⁰, Britta Maurer²¹, Alessandro Giollo¹⁸, Florenzo Iannone²², Lorenzo Dagna²³, Marie-Elise Truchetet²⁴, Masataka Kuwana²⁵, Yannick ALLANORE²⁶, Yoshiya Tanaka²⁷, Mickael Martin²⁸, Edoardo Rosato²⁹, Ana Maria Gheorghiu³⁰, Francesco Del Galdo³¹, Kamal Solanki³², Alessandra Vacca³³, CATARINA RESENDE³⁴, SUSANA VIEIRA³⁵, Laszlo Czirjak³⁶, Marko Barisic³⁷, Francesco Paolo Cantatore³⁸, valeria Riccieri³⁹, Kristofer Andréasson⁴⁰, Lorinda Chung⁴¹, Carolina Muller⁴², Daniela OPRIS-BELINSKI⁴³, Simona Rednic⁴⁴, Petros Sfikakis⁴⁵, Yair Levy⁴⁶, Anna Maria Hoffmann-Vold⁴⁷, Oliver Distler¹, Vivien Hsu⁴⁸, Stefan Heitmann⁴⁹, Gianluca Moroncini⁵⁰, Michele Iudici⁵¹, Joerg Henes⁵², Ellen De Langhe⁵³, Ariane Herrick⁵⁴ and Carlomaurizio Montecucco⁵⁵, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Oslo University Hospital, Oslo, Norway, ³Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, ⁴University of Lille, Lille, France, ⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, ⁷Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ⁸Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁹Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ¹⁰Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹¹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹²Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, ¹³Leiden University Medical Center, Leiden, Netherlands, ¹⁴University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹⁵Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ¹⁶Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁷Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ¹⁸Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, ¹⁹Ghent University Hospital, Gent, Belgium, ²⁰University College London, London, United Kingdom, ²¹University Hospital Bern, University Bern, Bern, Switzerland, ²²Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ²³Ospedale San Raffaele, Milano, Italy, ²⁴Bordeaux University Hospital, Bordeaux, France, ²⁵Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁶Université Paris Cité, Paris, France, ²⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁸Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, ²⁹Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy, ³⁰Department of Internal Medicine and Rheumatology, Ion Cantacuzino Clinical Hospital, Bucharest, Romania, ³¹University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ³²Department of Rheumatology, Te Whatu Ora Health New Zealand Waikato, Hamilton, New Zealand, ³³II Chair of Rheumatology, University of Cagliari-Policlinico Universitario, Monserrato, Italy, ³⁴Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Lisboa, Portugal, ³⁵Hospital Fernando Fonseca, Lisbon, Portugal, ³⁶Dept. Rheumatol Immunol, Medical School, university of Pecs, Pecs, Hungary, ³⁷Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia, ³⁸Rheumatology Clinic – Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, ³⁹Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy, ⁴⁰Lund University, Lund, Sweden, ⁴¹Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁴²Federal University of Parana, CURITIBA / PR, Brazil, ⁴³Saint Mary Hospital, Bucharest, Romania, ⁴⁴Prof Dr Simona Rednic, Cluj, Romania, ⁴⁵National Kapodistrian University of Athens Medical School, Athens, Greece, ⁴⁶Meir Medical Center, Autoimmune Research Laboratory, Kfar-Saba, Israel, ⁴⁷Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ⁴⁸Rutgers-RWJ Medical School, South Plainfield, NJ, ⁴⁹Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199, Stuttgart, Germany, ⁵⁰Marche Polytechnic University, Ancona, Italy, ⁵¹Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, ⁵²University Hospital Tuebingen, Tuebingen, Germany, ⁵³Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium, ⁵⁴University of Manchester, Salford, United Kingdom, ⁵⁵Unità Operativa e Cattedra di Reumatologia, IRCCS Policlinico S Matteo, Pavia, Italy
Background/Purpose: Systemic sclerosis (SSc) associated pre-capillary pulmonary hypertension (precapPH) is a severe condition that requires prompt treatment. Although immunosuppressants (IMS) are standard of care for…
Abstract Number: 1702 • ACR Convergence 2023
Outcomes in Systemic Sclerosis Patients Treated with Rituximab and Mycophenolate Mofetil Combination Therapy Compared to Autologous Hematological Stem Cell Transplantation
shiri keret¹, Lisa Kaly², Aniela Shouval², Tsila Zuckerman³, Israel Henig⁴, Abid Awisat⁵, Itzhak Rosner⁶, Michel Rozenbaum², Nina Boulman², Yair Molad⁷, ariela Dortort Lazar⁸, Gleb Slobodin² and Doron Rimar², ¹Bnai Zion, Atlit, Israel, ²Bnai Zion Medical Center, Haifa, Israel, ³Hematology department, Rambam Medical Center, Haifa, Israel, ⁴Stem cell transplantation unit, Hematology department, Rambam Medical Center, Haifa, Israel, ⁵Bney-Zion Medical Center, Baqa Elgharbiya, Israel, ⁶Bnai Zion Medical Center/Technion, Haifa, Israel, ⁷Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, ⁸Rabin Medical Center and Tel Aviv university, Tel Aviv, Israel
Background/Purpose: Autologous hematological stem cell transplantation (AHSCT) is a grade A therapy for early diffuse progressive systemic sclerosis (SSc), that has been validated in three…
Abstract Number: 1692 • ACR Convergence 2023
Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study)
Romain Aymon¹, Denis Mongin², Burkhard Leeb³, Monika Mustak-Blagusz⁴, Jakub Závada⁵, Karel Pavelka⁶, Dan Nordstrom⁷, Nina Trokovic⁸, Florenzo Iannone⁹, Catalin Codreanu¹⁰, Ziga Rotar¹¹, Tore Kvien¹², Sella Provan¹³, Manuel Enrique Pombo Suarez¹⁴, Fernando Alonso¹⁵, Fatos Onen¹⁶, Nevsun Inanc¹⁷, Louis Coupal¹⁸, Denis Choquette¹⁹, Galina Lukina²⁰, Ori Elkayam²¹, Victoria Furer²¹, Ana Maria Rodrigues²², Delphine COURVOISIER²³, Axel Finckh²⁴, Michael Nissen² and Kim Lauper²⁵, ¹Geneva University Hospitals, Collonges-sous-Salève, France, ²Geneva University Hospitals, Geneva, Switzerland, ³BioReg, Stockerau, Austria, ⁴BioReg, Vienna, Austria, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁷Helsinki University Hospital, Helsinki, Finland, ⁸University of Helsinki, Helsinki, Finland, ⁹Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁰Center for Rheumatic Diseases, Bucharest, Romania, ¹¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹²Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹³Diakonhjemmet Hospital, Oslo, Norway, ¹⁴Hospital Clínico Universitario, Santiago de Compostela, Spain, ¹⁵Spanish Society of Rheumatology, Madrid, Spain, ¹⁶Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁷Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, ¹⁸Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁹Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ²⁰Federal state budgetary scientific institution "V.A. Nasonova Research Institute of Rheumatology", Moscow, Russia, ²¹Tel Aviv Medical Center, Tel Aviv, Israel, ²²Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ²³Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²⁴HUG, Geneva, Switzerland, ²⁵Geneva University Hospitals, Genève, Switzerland
Background/Purpose: JAK-inhibitors (JAKi) are increasingly being prescribed to treat various inflammatory conditions, including psoriatic arthritis (PsA). While the understanding of JAKi efficacy and safety in…
Abstract Number: 1685 • ACR Convergence 2023
SLE Disease Activity Is a More Important Risk Factor Than Immunosuppression for Acquiring Human Papillomavirus (HPV) Infection in Systemic Lupus Erythematosus Patients
Zehra Kazmi¹, Carlos Lorenzo² and Agustin Escalante³, ¹University of Texas Health Science Center at San Antonio, San Antonio, TX, ²UT Heath San Antonio, Shavano Park, TX, ³UT Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: SLE patients have increased rates of HPV infection and cervical cancer. Although some factors are recognized for HPV infection in SLE, the relationship with…
Abstract Number: 1700 • ACR Convergence 2023
Incidence and Risk Factors for New Onset of Interstitial Lung Disease in Systemic Sclerosis: A EUSTAR Analysis
liubov Petelytska¹, Arthiha Velauthapillai², Lorenzo Tofani³, Eric Hachulla⁴, Ulf Müller-Ladner⁵, Elise Siegert⁶, Yannick ALLANORE⁷, Gabriela Riemekasten⁸, Christina Bergmann⁹, Radim Becvar¹⁰, Kamal Solanki¹¹, Branimir Anic¹², Simona Rednic¹³, Bojana Stamenkovic¹⁴, Lisa Stamp¹⁵, Joerg Distler¹⁶, Madelon Vonk¹⁷, Jeska de Vries-Bouwstra¹⁸, Anna Maria Hoffmann-Vold¹⁹, marco Matucci Cerinic²⁰, Oliver Distler²¹ and Cosimo Bruni²¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, ⁴University of Lille, Lille, France, ⁵Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ⁶Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁷Université Paris Cité, Paris, France, ⁸University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ⁹Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ¹⁰Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic, ¹¹Department of Rheumatology, Te Whatu Ora Health New Zealand Waikato, Hamilton, New Zealand, ¹²Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Kišpatićeva 12, 10 000, Zagreb, Croatia, ¹³Prof Dr Simona Rednic, Cluj, Romania, ¹⁴Institut Niska Banja, Niska Banja, Serbia, ¹⁵University of Otago, Christchurch, New Zealand, ¹⁶Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ¹⁷Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁸Leiden University Medical Center, Leiden, Netherlands, ¹⁹Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ²⁰Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ²¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Although prevalence of interstitial lung disease (ILD) in systemic sclerosis (SSc) and associated risk factors are established, less is known about its incidence and…
Abstract Number: 1695 • ACR Convergence 2023
Single Cell Transcriptomics in Kidney Tissue from African American Patients Enrolled in the Accelerating Medicines Partnership (AMP) Implicates Tubular Cells in the Pathogenesis of APOL1 Associated Lupus Nephritis
Philip Carlucci¹, Jasmine Shwetar², Siddarth Gurajala³, Qian Xiao³, Joseph Mears⁴, Katie Preisinger¹, Devyn Zaminski⁵, Kristina Deonaraine¹, Peter Izmirly¹, Andrea Fava⁶, Judith James⁷, Joel Guthridge⁷, Brad Rovin⁸, Sethu Madhavan⁸, Wade DeJager⁷, David Wofsy⁹, Ming Wu², Chaim Putterman¹⁰, Deepak Rao¹¹, Betty Diamond¹², Derek Fine¹³, Jose Monroy-Trujillo¹³, Kristin Haag¹⁴, H Michael Belmont⁵, William Apruzzese¹¹, Anne Davidson¹², Fernanda Payan-Schober¹⁵, Richard Furie¹⁶, Paul Hoover¹¹, Celine Berthier¹⁷, Maria Dall'Era⁹, Kerry Cho¹⁸, Diane L. Kamen¹⁹, Kenneth Kalunian²⁰, Jennifer Anolik²¹, Arnon Arazi²², Soumya Raychaudhuri¹¹, Nir Hacohen²³, Michelle Petri²⁴, Robert Clancy²⁵, Kelly Ruggles², Jill Buyon²⁵ and The Accelerating Medicines Partnership in RA/SLE²⁶, ¹New York University School of Medicine, New York, NY, ²NYU Langone, New York, NY, ³Harvard Medical School, Boston, MA, ⁴Michigan University, Ann Arbor, MI, ⁵NYU School of Medicine, New York, NY, ⁶Johns Hopkins University, Baltimore, MD, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Ohio State University, Columbus, OH, ⁹University of California San Francisco, San Francisco, CA, ¹⁰Albert Einstein College of Medicine, Bronx, NY, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Johns Hopkins School of Medicine, Baltimore, MD, ¹⁴Thomas Jefferson University, Philadelphia, PA, ¹⁵Texas Tech University Health Sciences Center, El Paso, TX, ¹⁶Northwell Health, Manhasset, NY, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸UCSF Health, San Francisco, CA, ¹⁹Medical University of South Carolina, Charleston, SC, ²⁰University of California San Diego, La Jolla, CA, ²¹University of Rochester Medical Center, Rochester, NY, ²²Broad Institute of MIT and Harvard, Melrose, MA, ²³Broad Institute of MIT and Harvard, Cambridge, MA, ²⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁵NYU Grossman School of Medicine, New York, NY, ²⁶Multiple, Bethesda, MD
Background/Purpose: The G1 and G2 risk variants (RVs) in Apolipoprotein L1 (APOL1) associate with CKD and may contribute to poorer outcomes for African American (AA)…
Abstract Number: 1676 • ACR Convergence 2023
Tofacitinib Accelerates in Vitro Clot Formation and Delays Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of Macrophage TLR4 Mediated Cytokine Responses- a New Angle on Thrombosis with JAKi in Rheumatology
Paula David¹, Thomas Macleod², Yu Shi³, Payal Ganguly¹, Cedric Duval³, Mark Harland¹, Chi Wong¹, Benazir Saleem⁴ and Dennis McGonagle⁵, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, United Kingdom, ²University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ³Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Teaching Hospitals NHS Trust, Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, ⁵Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) patients treated with Janus Kinase inhibitors (JAKi) have reportedly higher venous thromboembolism (VTE) risk and atherosclerotic-related complications including myocardial infarction (1).Although…
Abstract Number: 1684 • ACR Convergence 2023
The Impact of Pregnancy Timing on Outcomes in SLE
Catherine Sims¹, Amanda Eudy², Ceshae Harding¹, Cuoghi Edens³, Mehret Birru Talabi⁴, Rosalind Ramsey-Goldman⁵, Laura Neil¹ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke University, Raleigh, NC, ³University of Chicago, Chicago, IL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Northwestern University, Chicago, IL, ⁶Duke University, Chapel Hill, NC
Background/Purpose: To minimize risk of poor pregnancy outcomes, the ACR Reproductive Health Guideline recommends women conceive when SLE is well controlled and treated with pregnancy-compatible…
Abstract Number: 1397 • ACR Convergence 2023
Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Victoria Navarro-Compán¹, Lianne Gensler², Martin Rudwaleit³, Fabiana Ganz⁴, Shirley Chen⁴, Jayne Stigler⁴, Anna Schmagel⁴ and Xenofon Baraliakos⁵, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, ³University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁴AbbVie, Inc., North Chicago, IL, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany
Background/Purpose: Upadacitinib 15 mg (UPA), an oral Janus kinase inhibitor, has shown efficacy and tolerability through 14 weeks in patients (pts) with active radiographic axial…
Abstract Number: 1696 • ACR Convergence 2023
Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis
Michael A. Smith¹, Dominic Sinibaldi², Saifur Rahman¹, Chia-Chien Chiang², Anna M. Hansen¹, Jill Henault¹, Carlos P. Roca³, Shu Wang¹, Kamelia Zerrouki¹, Rebecca Filippi¹, Christopher Groves¹, Zerai Manna⁴, Jun Chu⁴, Michael Davis⁴, sarthak gupta⁴, Christopher Morehouse¹, Melissa De los Reyes¹, Rachel Ettinger¹, Roland Kolbeck¹, Mariana Kaplan⁵, Miguel A. Sanjuan¹, Richard M. Siegel⁶, sarfaraz Hasni⁴ and Kerry A. Casey¹, ¹BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Data Science and AI, AstraZeneca, Gaithersburg, MD, ³Data Science and AI, AstraZeneca, Cambridge, United Kingdom, ⁴Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁵Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁶Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…
Abstract Number: 1597 • ACR Convergence 2023
Staphylococcus Aureus Peptidoglycan Induces Pathogenic Autoantibody Production via Autoreactive B Cell Receptor Clonal Selection, Implications in Systemic Lupus Erythematosus
Wangbin Ning, Gary Gilkeson and Wei Jiang, Medical University of South Carolina, Charleston, SC
Background/Purpose: There is an intricate interplay between the microbiome and the immune response impacting the development of normal immunity and autoimmunity. However, we do not…
Abstract Number: 1409 • ACR Convergence 2023
Analysis of Soluble Biomarkers in Axial Spondyloarthritis
Caroline Bauchiero¹, Stephanie Sinnappan² and Joerg Ermann³, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Distinguishing patients with axial spondyloarthritis (axSpA) from patients with other causes of chronic back pain remains a challenge. The lack of reliable biomarkers contributes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].